Long-term administration of l-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …

The long-term use of levodopa (L-DOPA) in Parkinson's disease (PD) results in the
development of abnormal involuntary movements called L-DOPA-induced dyskinesias …

Levodopa is the most commonly prescribed drug for Parkinson's disease (PD). Although
levodopa improves PD symptoms in the initial stages of the disease, its long-term use is …

Pharmacological manipulation of the endocannabinoid system represents a promising
therapy to alleviate L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in …

Drugs acting at cannabinoid type 1 receptors (CB1) have modulatory effects on glutamate
and GABA neurotransmission in basal ganglia; thus, they potentially affect motor behavior in …

L-dopa induced dyskinesia (LID) is a debilitating side-effect of the primary treatment used in
Parkinson's disease (PD), l-dopa. Here we investigate the effect of HU-308, a cannabinoid …

Abstract l-Dopa is the most effective drug used for Parkinson's disease (PD), but after long-
term treatment, the vast majority of PD patients develop abnormal involuntary movements …

Parkinson's disease is the second most prevalent neurodegenerative disease in the world.
Its treatment is limited so far to the management of parkinsonian symptoms with L-DOPA …

The long-term use of levodopa as a pharmacotherapy for Parkinson's disease is limited by
the development of levodopa-induced dyskinesias. However, recent studies have suggested …

The dopamine precursor L-3, 4-dihydroxyphenylalanine (L-DOPA) has been used as an
effective drug for treating dopamine depletion-induced Parkinson's disease (PD). However …